Combination therapy with ianalumab (a BAFF-R monoclonal antibody) and eltrombopag significantly prolonged the time to treatment failure in adults with primary immune thrombocytopenia (ITP).
The estimated probability of freedom from treatment failure at 12 months was 54% in the 9-mg ianalumab group versus 30% in the placebo group.
Stable response rates at six months were markedly higher with the 9-mg dose of ianalumab (62%) compared to placebo (39%).
Ianalumab was administered as a short 4-month course, potentially offering a path toward treatment-free remission in a disease often requiring chronic medication.
Introduction: The Challenge of Chronic ITP Management
